Table 1.
Clinical characteristics & KT related data of included KTRs (n = 83)
| Age at transplantation (years) | Mean ± SD | 9.3 ± 2.9 | |
|---|---|---|---|
| Post-transplant follow-up duration (months) | median (IQR) | 60 (36–93) | |
| Original kidney disease | CAKUT | N (%) | 42 (50.6%) |
| NONE CAKUT | N (%) | 41 (49.4%) | |
| Family history of any kidney disease | N (%) | 6 (7.2%) | |
| Patients required hemodialysis before transplantation | N (%) | 79 (95.2%) | |
| Pre-epmptive kidney transplantation | N (%) | 4 (4.8%) | |
| Hemodialysis duration (months) | median (IQR) | 12 (1–60) | |
| Native nephrectomy | No | N (%) | 43 (51.8%) |
| Unilateral | N (%) | 12 (14.5%) | |
| Bilateral | N (%) | 28 (33.7%) | |
| Cause of nephrectomy | Heavy proteinuria | N (%) | 17 (42.5%) |
| Large polycystic kidney | N (%) | 2 (5%) | |
| Pyelonephritic kidney | N (%) | 6 (15%) | |
| Marked hydronephrosis | N (%) | 15 (37.5%) | |
| Anthropometric measures at enrollment in the study | Weight (Kg) | Mean ± SD | 37 ± 11.9 |
| Height (m) | Mean ± SD | 1.36 ± 0.17 | |
| BMI (kg/m2) | Mean ± SD | 19.4 ± 4.5 | |
| *CMV risk stratification | Low risk | N (%) | 8 (9.6%) |
| Intermediate | N (%) | 70 (84.3%) | |
| High risk | N (%) | 5 (6%) | |
| Donor/recipient HLA mismatch | 4/6 | N (%) | 3 (3.6%) |
| 3/6 | N (%) | 50 (60.2%) | |
| 2/6 | N (%) | 25 (30.1%) | |
| 1/6 | N (%) | 3 (3.6%) | |
| 0/6 | N (%) | 2 (2.4%) | |
| Antibody induction therapy | Basiliximab | N (%) | 43 (51.8%) |
| ATG | N (%) | 40 (48.2%) | |
| Preemptive PEX | N (%) | 15 (18.1%) | |
| Maintenance IS other than TAC | MMF | N (%) | 82 (98.8%) |
| Azathioprine | N (%) | 1 (1.2%) | |
KT; kidney transplantation, KTR ; kidney transplant recipients, N; number, SD; standard deviation, IQR; interquartile range, CAKUT; congenital anomalies of kidney and urinary tract, Kg; kilograms, m; meter, BMI; body mass index, CMV; cytomegalo virus, HLA; human leukocytic antigen, ATG: anti thymocyte globulin, PEX; plasma exchange, IS; immunosuppressive, TAC; tacrolimus, MMF; mycophenolic mofetil.* CMV IgG: Low risk (D -, R -), intermediate risk either (D+, R+) or (D-, R+), high risk (D+, R-)